Background-Bivalirudin, a direct thrombin inhibitor, is a widely used adjunctive therapy in patients undergoing percutaneous intervention (PCI). Thrombin is a highly potent agonist of platelets and activates the protease-activated receptors, PAR1 and PAR4, but it is not known whether bivalirudin exerts antiplatelet effects in PCI patients. We tested the hypothesis that bivalirudin acts as an antiplatelet agent in PCI patients by preventing activation of PARs on the platelet surface. Methods and Results-The effect of bivalirudin on platelet function and systemic thrombin levels was assessed in patients undergoing elective PCI. Mean plasma levels of bivalirudin were 2.7Ϯ0.5 mol/L during PCI, which correlated with marked inhibition of thrombin-induced platelet aggregation and significantly inhibited cleavage of PAR1. Unexpectedly, bivalirudin also significantly inhibited collagen-platelet aggregation during PCI. Collagen induced a conversion of the platelet surface to a procoagulant state in a thrombin-dependent manner that was blocked by bivalirudin. Consistent with this result, bivalirudin reduced systemic thrombin levels by Ͼ50% during PCI. Termination of the bivalirudin infusion resulted in rapid clearance of the drug with a half-life of 29.3 minutes.
M ost treatment strategies for acute coronary syndromes or adjunctive therapy for PCI are aimed at inhibiting thrombin and platelet activity. The synthetic, direct thrombin inhibitor bivalirudin (Angiomax) is approved for use as an antithrombotic agent in patients undergoing PCI. Bivalirudin binds reversibly to thrombin at both its active site and exosite I, 1 and inhibits both circulating and thrombus-bound thrombin. 2 The safety and efficacy of bivalirudin in patients undergoing PCI has been assessed in patients with stable angina, unstable coronary syndromes, and acute ST-elevation myocardial infarction. In general, these trials [3] [4] [5] have documented that bivalirudin therapy during PCI is associated with noninferior ischemic end points with significant reductions in the rates of major hemorrhage compared with heparin plus a GPIIb/IIIa inhibitor. However, the efficacy of adjunctive therapy as judged by the occurrence of ischemic complications during and after PCI is strongly influenced by platelet function. 6 Therefore, the clinical trial data indicate that bivalirudin might provide significant antiplatelet in addition to anticoagulant effects during PCI.
Clinical Perspective on p 179
Thrombin, a primary mediator of platelet activation and aggregation through the PAR1 and PAR4 thrombin receptors, 7, 8 has been shown to be elevated as a consequence of PCI wherein local thrombin activity in the culprit artery is greatly increased. 9, 10 Whether bivalirudin affects PARdependent platelet function and ongoing thrombin generation in patients undergoing PCI is not clear. [11] [12] [13] Moreover, the association between the currently used dosage of bivalirudin and suppression of platelet aggregation by the two major agonists thrombin and collagen has not been determined in patients undergoing PCI.
In the present study, we assessed the degree of protection from thrombin-induced platelet activation conferred by the clinically used dosages of bivalirudin in patients undergoing PCI. We also studied the effect of bivalirudin on systemic thrombin-antithrombin III levels and its effect on collageninduced platelet aggregation and platelet procoagulant activ-ity. For the first time, the plasma levels and half-life of bivalirudin was quantified at doses currently used during PCI. The data presented here support the concept that bivalirudin is not solely an anticoagulant, but also attenuates platelet activation via inhibition of platelet thrombin receptors and collagen-dependent thrombin generation.
Methods

Patient Population
This mechanistic study examined the antiplatelet effects of bivalirudin, an approved adjunctive agent for PCI using its commonly used dose in the approved patient population for this drug. Outpatients with angina referred for coronary angiography or PCI who had not received clopidogrel within 2 weeks were enrolled in the Tufts Medical Center Adult Cardiac Catheterization Laboratory. The population studied was relatively low risk; patient characteristics are summarized in Table 1 . Inclusion criteria included men and nonpregnant women, age 18 years or older, referred for possible PCI who were eligible for bivalirudin therapy. All patients provided written informed consent before the initiation of the study. The study protocol was approved by the Tufts Medical Center Institutional Review Board. Exclusion criteria included current therapy with heparin or GPIIb/IIIa inhibitors, serum creatinine level Ͼ2.0 mg/dL, known hypersensitivity to bivalirudin, clopidogrel or aspirin, thrombocytopenia (platelet count Ͻ50 000/L), severe systemic hypertension defined as systolic blood pressure Ͼ180 mm Hg and/or diastolic blood pressure Ͼ110 mm Hg, acute pericarditis, active internal bleeding, history of bleeding diathesis within the past 30 days, history of intracranial hemorrhage, arteriovenous malformations or aneurysms, ischemic stroke within the past 30 days, major surgical procedures or severe physical trauma within the past 30 days, symptoms or findings suggestive of aortic dissection, pregnancy and participation in other clinical research studies within 30 days of enrollment. Eligible patients received the same weight-adjusted dosage of bivalirudin administered intravenously as a 0.75 mg/kg bolus followed by continuous infusion of 1.75 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 during the procedure. All patients were chronic aspirin users and received aspirin before the intervention. Oral clopidogrel (600 mg) was administered at the completion of PCI to patients who received coronary stents; these patients were subsequently discharged with a prescription of 75 mg clopidogrel daily.
Platelet Aggregation Studies in Patients
Venous blood samples were collected from PCI patients at baseline and at 30 minutes after initiation of bivalirudin infusion, using a 18-gauge needle and a 20-mL syringe prefilled with 2 mL of 4% sodium citrate. Whole blood was transferred into 15-mL polypropylene tubes with EDTA added for a final concentration of 0.25 mmol/L. To prevent loss or dilution of bivalirudin from the patient samples, platelet-rich plasma (PRP) rather than washed platelets was used in all the aggregation experiments. PRP was harvested by centrifuging blood at 700g for 20 minutes at 30°C. To prevent fibrin formation on addition of thrombin agonist, the peptide glycine-L-prolyl-L-arginyl-L-proline (GPRP) (Sigma) was added (1 mmol/L final concentration) to the PRP before performing platelet aggregation. Platelet aggregation was induced by 3 nmol/L to 1 mol/L thrombin (Hematologic Technologies), 5 g/mL fibrillar type I collagen (Chronolog), 5 mol/L SFLLRN or 160 mol/L AYPGKF (synthesized with C-terminal amides at the Tufts Peptide Core Facility). Platelet aggregation was measured with a Chronolog 560VS/490 to 2D aggregometer with platelet-poor plasma serving as blank. Samples were recalcified with CaCl 2 (2.5 mmol/L final concentration) before addition of agonists. All reactions were conducted in final volumes of 250 L at 37°C while stirring at 900 rpm.
Quantification of Bivalirudin Concentration in Plasma
Bivalirudin levels in plasma were obtained from PCI patients just before bivalirudin infusion (baseline), immediately following bolus infusion, 30 minutes following the institution of the continuous infusion, or at the end of PCI if the procedure was completed earlier (30 minutes), 5 minutes after termination of infusion (5 minutes POST), 15 minutes after termination of infusion (15 minutes POST), and 2 hours after termination of infusion (2 hours POST). Whole blood was drawn into 6-mL EDTA-containing test tubes and immediately transferred to ice. Platelet-poor plasma samples were stored at Ϫ80°C. Platelet-poor plasma samples were shipped on dry ice to Frontage Laboratories (Malvern, PA) for determination of plasma drug levels using a Q-Trap 5000 MS/MS system equipped with an high-performance liquid chromatography. The threshold level of detection of bivalirudin in plasma was 0.23 mol/L by liquid chromatography tandem mass spectrometry.
Platelet Aggregation of Blood Samples From Healthy Volunteers
Blood was obtained from adult healthy volunteers (nϭ10, 5 males, 5 females) from the greater Boston area recruited by Tufts institutional review board-approved procedures. PRP was obtained from the healthy volunteers in an identical manner as the PCI patients. To obtain the standard bivalirudin inhibition curves, various concentrations (0.1 to 10 mol/L) of bivalirudin were preincubated with PRP for 2 minutes before addition of thrombin. Platelet aggregation assay was performed in an identical manner as with the PRP from patients. Thrombin median effective concentration (EC 50 ) values were plotted as a function of bivalirudin concentration. To measure the effects of the presence of plasma proteins on collagen-and thrombin-induced aggregation, gel-filtered platelets were further prepared from healthy-volunteer PRP using Sepharose 2B columns in modified PIPES buffer as previously described. 15 Platelet aggregation was measured using PIPES buffer as control. Inhibitors were added 2 minutes before addition of collagen or thrombin agonists.
Prothrombinase, Thrombin-Antithrombin III, and Thromboxane B 2 Assays
Thrombin generation was quantified in citrate-anticoagulated human PRP as described 16 with simple modifications. In brief, 250 L of 
Platelets (thousand/L) 223Ϯ39
Patients receiving coronary stents 86%
Urgent reocclusion None
Post-PCI myocardial infarction None
Death None
Minor or major hemorrhage None Data are reported as meanϮSD. TIMI indicates thrombolysis in myocardial infarction; CK-MB, creatine kinase MB; PCI, percutaneous coronary intervention.
PRP from healthy donors was recalcified with CaCl 2 (final, 2.5 mmol/L) and stimulated with 5 g/mL collagen for 5 minutes at 37°C while stirring at 200 rpm. Bivalirudin was added 3 minutes before collagen. Thrombin generation was quenched by addition of 20 mmol/L EDTA in HEPES buffer, pH 7.5, on ice. Thrombin activity was measured using the chromogenic substrate S2238 as described. 17 Quantification of thrombin-antithrombin III (TAT) complexes and Thromboxane B 2 (TXB 2 ) in the plasma from PCI patients obtained at baseline, 30 minutes after PCI, and 120 minutes after termination of bivalirudin infusion was performed by ELISA using commercially available kits (Affinity Biologicals, Cayman Chemicals, respectively) and following the manufacturer's protocols. TAT and TXB 2 ELISAs used 20 L of plasma and 80 L of buffer per assay well.
Annexin V and Span-12 Binding
Whole blood from healthy donors was diluted 1:10 in modified HEPES-Tyrodes buffer (10 mmol/L HEPES, 137 mmol/L NaCl, 2.8 mmol/L KCl, 1 mmol/L MgCl 2 , 12 mmol/L NaHCO 3 , 0.4 mmol/L Na 2 PO 4 , 5.5 mmol/L glucose, and 0.35% BSA, pH 7.4). GPRP at a final concentration of 1 mmol/L was added to prevent fibrin polymerization before addition of agonists. Diluted whole blood was incubated for 10 minutes with bivalirudin or PIPES buffer and then incubated for an additional 10 minutes with 5 g/mL collagen, 20 to 50 nmol/L thrombin, or both at 37°C. The samples were labeled with CD41a-PE antibody alone or with a mixture of CD41a-PE antibody and annexin V-FITC (BD Biosciences) in the dark at room temperature for 30 minutes. Paraformaldehyde 1% was used to fix the platelets. Analysis was performed on a BD FAC-SCanto II Flow Cytometry System. Platelets were gated against the CD41a-PE-Ab channel and their characteristic log orthogonal and forward light scatter used to eliminate non-platelet-derived events and debris. For Span-12 antibody binding, PRP anticoagulated with citrate plus 1 mmol/L GPRP was obtained from PCI patients at baseline or after 30 minutes PCI, or from healthy volunteers. PRP was treated with 20 nmol/L thrombin at 37°C for 15 minutes. Samples were then labeled with 1:1000 PAR1 antibody, Span 12-PE (which recognizes only intact PAR1), at room temperature for 30 minutes and then fixed with 1% paraformaldehyde and assessed by fluorescence-activated cell sorting (FACS) as above.
Data Analysis
We quantified the degree of platelet inhibition conferred by bivalirudin during PCI by use of thrombin, AYPGKF, SFLLRN, and collagen as agonists. From our previous bivalirudin spiking study 8 with healthy subjects using a standard deviation (SD) of 10%, and choosing a power of 95% and with an ␣ϭ0.05, we calculated that we would require at least 9 subjects to obtain a significant result if the true differences between baseline and the bivalirudin treatment groups were as small as 20%. Statistical analyses were performed with GraphPad Prism5.0a using a paired 2-tailed Student t test. Pairwise comparisons of aggregometry results for each agonist were made between baseline (before receiving bivalirudin) and at the 30-minute time point.
Results
Bivalirudin Efficiently Inhibits Thrombin-Induced Aggregation in Platelets from Patients Undergoing PCI
The demographic, clinical, and procedural characteristics of the 22 patients comprising the study population are listed in Table 1 . Although this mechanistic study was neither designed nor powered to assess clinical outcomes, no patient experienced an ischemic end point or major or minor bleeding according to thrombolysis in myocardial infarction criteria. 14 We first assessed the effects of bivalirudin on thrombin-, SFLLRN-, and AYPGKF-induced aggregation in platelet-rich plasma from the patients undergoing PCI. Thrombin is a potent agonist of both the PAR1 and PAR4 thrombin receptors, SFLLRN specifically activates PAR1, and AYPGKF specifically activates PAR4. 8, 18, 19 Bivalirudin completely blocked platelet aggregation in response to high concentrations of exogenously added thrombin at the 30minute time point during the PCI procedure in all patients ( Table 2 ). We next determined the concentration of thrombin that would overcome the inhibitory effects of the infused bivalirudin on platelets from each patient. Bivalirudin markedly right-shifted the thrombin aggregation curves by 26-fold to a mean thrombin EC 50 of 256Ϯ87 nmol/L in the patients undergoing PCI ( Figure 1A through 1C ). However, the bivalirudin infusion had no significant effect on mean platelet aggregation in response to the synthetic peptide agonists SFLLRN or AYPGKF in the patients compared with baseline ( Table 2) .
PAR1 is the high-affinity thrombin receptor on platelets and its activation is highly dependent on interactions between thrombin exosite I and the hirudin-like domain on the PAR1 extracellular domain. 7 Because bivalirudin also binds with high affinity to exosite I of thrombin, we postulated that bivalirudin might inhibit thrombin cleavage of PAR1 on the surface of platelets. The Span12 antibody, which binds only to uncleaved PAR1, was used to quantify thrombin cleavage of PAR1 on the platelet surface. We found that 20 nmol/L thrombin caused 81% loss of Span12 binding to the platelet surface at baseline which was significantly protected by the 30 minutes bivalirudin infusion ( Figure 1D and 1E). Similar protection against thrombin cleavage of PAR1 was observed by adding exogenous bivalirudin to platelets from healthy volunteers ( Figure 1E ).
Pharmacokinetics of Bivalirudin in Patients Undergoing PCI
A previous pharmacokinetic study in PCI patients 20 using the first Food and Drug Administration-approved dosage regimen of bivalirudin based on the Bivalirudin Angioplasty Trial (bolus of 1.0 mg/kg followed by an infusion of 2.5 mg ⅐ kg Ϫ1 ⅐ 
*Platelets in PRP were isolated from PCI patients at baseline and after 30 minutes of bivalirudin infusion, and were stimulated with 50 nmol/L thrombin, 5 mol/L SFLLRN, 160 mol/L AYPGKF, and 5 g/mL collagen. Platelet aggregometry was performed at 37°C in the presence of 1 mmol/L GPRP. TAT and TXB 2 levels in plasma were analyzed by ELISA as described in Methods. Data are reported as meanϮSD, and P values were determined by paired t tests.
†Collagen-dependent aggregation was measured with 18 of the 22 PCI patients as shown in Figure 4A for individual patients.
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h Ϫ1 ), 21 yielded mean steady-state bivalirudin plasma levels of 5.6 mol/L (12.3Ϯ1.7 g/mL) and a terminal half-life of 25 minutes. However, the plasma levels and half-life of bivalirudin have not been determined using the current Food and Drug Administration-approved dosage regimen of bivalirudin established by the REPLACE-2 study 3 which uses a substantially reduced bivalirudin exposure (0.75 mg/kg bolus and 1.75 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 infusion) for the duration of the PCI procedure. Therefore, we measured circulating bivalirudin drug levels from 22 PCI patients both during and after termination of bivalirudin infusion. Peak drug levels reached 3.2Ϯ0.7 mol/L at the 5-to 10-minute time point just after the bolus injection (Figure 2 , online-only Data Supplement  Table) . The mean steady-state bivalirudin concentration during PCI was 2.7Ϯ0.5 mol/L, a Ͼ50% reduction in the bivalirudin levels relative to patients that received the original 1.0 mg/kg bolus and 2.5 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 infusion dosage. 22 The distribution of steady-state drug levels in individual patients ranged from a low of 1.7 mol/L to a high of 3.7 mol/L. Despite these individual differences, all patients had dramatic right-shifts in their thrombin EC 50 curves from a low of 150 nmol/L to a high of 570 nmol/L ( Figure 1C ). The thrombin-platelet aggregometry dose-response curve determined for a range of bivalirudin concentrations in whole blood gave a predicted mean plasma bivalirudin level of 3.1 mol/L which deviated by only 13% from the actual measured mean steady-state value of 2.7 mol/L in the patient samples ( Figure 1C ). After discontinuation of the infusion, bivalirudin was rapidly cleared from the plasma with a mean half-life of 29.3Ϯ15.3 minutes (online-only Data Supplement Table) . Two hours after discontinuation of the bivalirudin infusion, residual plasma drug levels (0.2 mol/L) were only 11% of the steady-state levels.
Bivalirudin Significantly Decreases Systemic TAT Levels in Patients Undergoing PCI
Patients with acute coronary syndromes have high systemic levels of various hemostatic markers that indicate an active prothrombotic and procoagulant state that can contribute to arterial thrombosis. 9, 10 The observation that bivalirudin decreases platelet activity leads to the prediction that systemic thrombin levels may be decreased from baseline following infusion of bivalirudin in the patients undergoing PCI. TAT complexes are rapidly formed when antithrombin III irreversibly binds to active thrombin; thus, circulating TAT complexes are a measure of systemic thrombin levels. Indeed, we found that the baseline mean systemic levels of TAT were 215Ϯ104 pmol/L (normal range, 10 to 30 pmol/L) in our PCI patients. Given that TAT complexes have a very short plasma half-life of 15 minutes, these highly elevated TAT levels suggest ongoing systemic thrombin generation. 9, 10 To assess the effect of bivalirudin on systemic thrombin, we compared plasma TAT levels at baseline, after 30 minutes of bivalirudin infusion, and 2 hours after cessation of bivalirudin. As shown in Figure 3 , the PCI patients had a significant drop in mean systemic TAT levels to 98Ϯ41 pmol/L ( Table 2) , 30 minutes after initiation of the bivalirudin infusion. Notably, there was no significant rebound in mean systemic TAT levels 2 hours (mean of 107Ϯ92 pmol/L) after termination of the bivalirudin infusion (Figure 3 ).
Bivalirudin Inhibits Collagen-Induced Platelet Activation
Bivalirudin unexpectedly caused a statistically significant inhibition of collagen-induced aggregation of platelet-rich plasma obtained from the PCI patients at the 30-minute time point compared with baseline (Table 2, Figure 4A ). The inhibitory effect of spiked bivalirudin on collagen-induced aggregation in platelet-rich plasma ( Figure 4B ) was not observed when plasma proteins were removed from the platelet preparations by gel filtration (Figure 4C ), consistent with previous data. 23 Addition of exogenous thrombin to plasma-depleted platelets gave 80% platelet aggregation, which was completely blocked by bivalirudin or the direct thrombin inhibitor, PPACK ( Figure 4D ). To rule out that the observed differences in collagen aggregation were because of variable inhibition of thromboxane pathways, we confirmed that plasma TXB 2 levels 24 were unchanged from baseline versus the 30-minute time point in the PCI patients (Table 2 ). This was expected because the patients were documented long-term aspirin users with 20 of the 22 patients receiving their last aspirin dose 4 hours before the procedure and 2 patients receiving their last aspirin dose just before the procedure.
Bivalirudin Inhibits Collagen-Dependent Platelet Procoagulant Activity
Given that inhibition of collagen-induced platelet aggregation by bivalirudin required the presence of plasma proteins (eg, 
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prothrombin and other coagulation factors), we tested the hypothesis that bivalirudin inhibits collagen-initiated aggregation by suppressing platelet-dependent thrombin generation. We used annexin V binding to assess the appearance of negatively charged phospholipids in individual platelets from PCI patients and healthy donors as a marker of procoagulant activity within the platelet population. 25 Addition of collagen to whole blood obtained from PCI patients at baseline or from healthy volunteers gave a large 6-to 20-fold increase in annexin V binding (30% positive platelets). The collageninduced increase in annexin V binding was significantly inhibited in the platelets obtained from the PCI patients after 30 minutes of bivalirudin infusion or by spiking whole blood from healthy volunteers with bivalirudin ( Figure 5A and 5B) . Consistent with previous data, 26 thrombin gave a 2-fold increase in annexin-V-positive platelets, which was inhibited in the whole blood obtained from PCI patients after 30 minutes of bivalirudin infusion or by addition of bivalirudin to whole blood from healthy volunteers. The combination of collagen plus thrombin gave a synergistic enhancement in annexin V binding, which was inhibited by bivalirudin in the PCI patients and by exogenously added bivalirudin in the healthy volunteers. Likewise, the direct thrombin inhibitor, PPACK, completely blocked annexin V staining in response to collagen or thrombin ( Figure 5B ). Platelets in platelet-rich plasma from healthy volunteers were then stimulated with collagen, and thrombin generation directly measured. As shown in Figure 5C , bivalirudin significantly inhibited thrombin generation triggered by exposure of the platelets to collagen. Together, these data indicate that bivalirudin can suppress collagen-induced platelet aggregation by blocking thrombin-dependent propagation of procoagulant activity on the platelet surface.
Discussion
In the present study, we demonstrated that bivalirudin, at the dose currently used during PCI, provides extensive protection from thrombin-induced platelet aggregation. At this dose, bivalirudin also suppressed systemic thrombin-antithrombin III levels by more than half and significantly inhibited collagen-induced platelet aggregation and generation of platelet thrombogenic surfaces. These findings demonstrate that bivalirudin has a hitherto unappreciated ability to inhibit both protease-activated receptor and collagen-dependent aggregation and platelet procoagulant activity in patients undergoing PCI. We also provide the first direct evidence that bivalirudin protects against thrombin cleavage of PAR1 on the platelet surface in PCI patients. Bivalirudin has become a widely used adjunctive therapy in a broad spectrum of patients with coronary artery disease undergoing PCI. Large clinical trials have documented the efficacy of bivalirudin compared with heparin plus GPIIb/IIIa inhibitors. 4, 5 Our study provides a mechanistic framework to suggest efficacy of bivalirudin as it relates to platelet-dependent ischemic events.
Thrombin is the most potent stimulator of platelet activation and thrombosis. 7, 27 Thrombin triggers platelet aggregation through the dual actions of both the PAR1 and PAR4 receptors. 7 PAR1 is a high-affinity receptor for thrombin by virtue of a hirudin (Hir)-like sequence that resides in its N-terminal extracellular domain. 19, 28, 29 The Hir sequence allows PAR1 to compete with the much more abundant fibrinogen, and as a result, PAR1 is activated by thrombin at subnanomolar concentrations. The present study showed that bivalirudin effectively suppressed cleavage of the extracellular domain of PAR1 on the platelet surface by even supraphysiologic concentrations of 50 nmol/L thrombin.
After cleaving PAR1, thrombin may remain tethered to PAR1 through the Hir sequence where it can cleave nearby
Platelet Number
Annexin V Fluorescence Figure 5 . Bivalirudin inhibits collagen-induced platelet procoagulant activity and thrombin generation. (A) Whole blood from percutaneous intervention (PCI) patients (nϭ5) at baseline or 30 minutes after initiation of PCI was diluted 10-fold into HEPES buffer and was incubated with the indicated agonists (5 g/mL collagen, 20 nmol/L thrombin, or 5 g/mL collagen plus 20 nmol/L thrombin). After 15 minutes, the platelet samples were stained with an annexin V antibody, and the percentage of platelets staining (M1 region) with the anionic phospholipid marker was quantified as described in Methods. (B) Whole blood from healthy donors were diluted as the patient samples in A and preincubated with the indicated concentrations of bivalirudin (mol/L) or 100 mol/L PPACK before addition of collagen and/or thrombin agonists. The percentage of annexin V binding positive (M1) for both healthy donors (nϭ6) and patients (nϭ5) are shown (meanϮSD). (C) platelet-rich plasma from a healthy donor was preincubated in the presence or absence of 5 mol/L bivalirudin for 2 minutes before the addition of 5 g/mL collagen. The amounts of thrombin generated (meanϮSD of triplicate samples) were determined as described in Methods. The experiment was done with 2 other healthy donors and gave similar results.ˆPϽ0.025, #PϽ0.017, ##PϽ0.001 by paired-sample t test with Bonferroni correction and *PϽ0.05 by paired-sample t test.
PAR4, which exists as a heterodimer in association with PAR1. 8, 19 PAR4 is cleaved more slowly than PAR1 mainly because it lacks a functional Hir sequence 30 and relies on PAR1 to play this critical helper function. 8 Thus, the Hir analog bivalirudin is an effective inhibitor of the interactions of thrombin with both PAR1 and PAR4. Given that the steady-state levels of bivalirudin achieved during PCI achieved complete blockade of 50 nmol/L thrombin-induced platelet activation, this study would strongly suggest that bivalirudin suppresses both PAR1-and PAR4-dependent platelet activation during PCI. The described effects of bivalirudin-mediated inhibition of thrombin-induced platelet aggregation with an absence of an effect on SFLLRN or AYPGKF indicates that the inhibitory effects of bivalirudin depends on its ability to prevent upstream thrombin activation of the platelet thrombin receptors but, as expected, does not affect platelet aggregation triggered by either of the synthetic PAR1 or PAR4 agonist peptides that bypass the requirement for thrombin cleavage. 19 The present study determined that the mean half-life of bivalirudin in the PCI patients was 29 minutes, which is approximately one-third the half-life of unfractionated heparin and is significantly less than the biological half-lives of the 3 commonly used GPIIb/IIIa inhibitors. 31 This rapid disappearance of bivalirudin from the plasma likely contributes to the relatively low incidence of acute bleeding complications observed in PCI patients that receive bivalirudin monotherapy compared with patients who receive the longerlived heparin and GPIIb/IIIa inhibitors.
We also provided evidence that bivalirudin negatively regulates on-going thrombin generation in PCI patients. Systemic thrombin, as reflected by antithrombin III-thrombin levels was significantly suppressed by bivalirudin in nearly all patients during the PCI procedure and did not rebound above baseline levels 2 hours after the bivalirudin infusion was terminated. Moreover, the majority of patients had postprocedural TAT levels that remained significantly suppressed at 2 hours compared with baseline. These data support the notion that bivalirudin targets both existing circulating thrombin and interrupts on-going procoagulant activity.
In this regard, we found that bivalirudin suppressed thrombin generation by blocking collagen-initiated platelet procoagulant activity. GPVI is the major collagen receptor that is a highly efficient activator of platelet procoagulant activity. 32 Indeed, previous studies showed that exposure of platelets to collagen lead to the appearance of a high percentage of negatively charged phospholipids, as reflected by annexin V binding to the platelet surface. 33, 34 The negatively charged phospholipids serve as a critical binding site for factor Va/Xa and accelerate the prothrombinase activity. The thrombin that is generated on the platelet surface, in turn, further activates platelets through the PARs 26, 35, 36 and generates more prothrombinase activity by additional thrombin cleavage and activation of factor V. Bivalirudin attenuates this collageninitiated platelet activation by inhibiting the thrombinpositive feedback loop. However, it remains to be determined whether the observed 11% drop in mean collagen-induced platelet aggregation provides a clinically significant protec-tive effect. Furthermore, it is unknown whether addition of a P2Y12 antagonist such as clopidogrel may either mask or augment these bivalirudin-mediated inhibitory effects on collagen in PCI patients.
Conflicting results have been reported on the efficacy of bivalirudin versus heparin on platelet function using FACS analysis. A recent study 11 reported that heparin, but not bivalirudin, inhibited subnanomolar thrombin cleavage and internalization of PAR1 on platelets from PCI patients. However, consistent with our earlier work, 8 a FACS study 12 showed that spiked bivalirudin blocked thrombin activation of the GPII/IIIa receptor and surface expression of P-selectin to a much greater extent than spiking blood with heparin or heparin plus eptifibatide. Likewise, another report 13 confirmed that bivalirudin completely blocks 10 nmol/L thrombin activation of GPIIb/IIIa and P-selectin immediately after the PCI procedure.
In conclusion, we found that bivalirudin infusion during PCI confers a substantial inhibitory effect on both thrombinand collagen-mediated platelet activation and reduces plasma thrombin concentrations. These effects, along with the short half-life of bivalirudin, likely contribute to its efficacy and safety when used as an adjunctive agent during PCI.
